Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
7 pending office actions • 4 art units • 7 examiners • 0 of 7 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Nihon Medi-Physics Co. Ltd. currently manages 7 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 7 distinct examiners, which indicates that every active matter is being reviewed by a different individual. The portfolio's progress depends on navigating a variety of examiner perspectives simultaneously rather than a single point of contact. This high level of diversification suggests that the company's overall prosecution success is not tied to the specific tendencies of any single examiner.
The company's active filings are spread across 4 distinct art units, which is fewer than the count of examiners. Sean R Donohue is identified as the busiest examiner for the portfolio, though he is responsible for only 1 pending office action. Because each of the 7 pending actions is handled by a different examiner, the workload is distributed across the identified individuals. This structure requires the company to maintain a prosecution strategy that can adapt to the requirements of the 4 different art units and the various examiners.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (29%) |
| §112 only | 1 (14%) |
| Double-patenting + other | 2 (29%) |
| Multi-statute (no §101) | 2 (29%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DONOHUE, SEAN R | 1 | 41.4% | +21.0% |
| SCHLIENTZ, LEAH H | 1 | 41.9% | +38.5% |
| JARRELL, NOBLE E | 1 | 81.1% | +9.7% |
| REYNOLDS, FRED H | 1 | 33.0% | +39.2% |
| DICKINSON, PAUL W | 1 | 63.1% | +9.5% |
| JONES, DAMERON LEVEST | 1 | 67.7% | +31.3% |
| ROBINSON, MIKHAIL O'DONNEL | 1 | 59.2% | +42.1% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18550479 | COMPOUND, METHOD FOR PRODUCING AND METHOD FOR STORING COMPOUND, METHOD FOR PRODUCING TARGETING AGENT, AND COMPOSITION | JARRELL, NOBLE E | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18005129 | METHOD FOR PRODUCING 225AC SOLUTION | DICKINSON, PAUL W | — |
| 17769657 | METHOD FOR PRODUCING RADIOACTIVE METAL-LABELED ANTIBODY | JONES, DAMERON LEVEST | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18249220 | RADIOACTIVE COMPLEXES OF ANTI-HER2 ANTIBODY, AND RADIOPHARMACEUTICAL | REYNOLDS, FRED H | 8d overdue |
| 18688001 | RADIOACTIVE COMPLEX OF DEGLYCOSYLATED ANTIBODY AND RADIOACTIVE PHARMACEUTICAL PRODUCT | DONOHUE, SEAN R | — |
| 18556577 | RADIOACTIVE ANTITUMOR AGENT | SCHLIENTZ, LEAH H | — |
| 17769657 | METHOD FOR PRODUCING RADIOACTIVE METAL-LABELED ANTIBODY | JONES, DAMERON LEVEST | — |
| 17632994 | METHOD FOR PRODUCING RADIOACTIVE METAL COMPLEX | ROBINSON, MIKHAIL O'DONNEL | — |
| Art Unit | Apps |
|---|---|
| 1618 | 3 |
| 1699 | 1 |
| 1658 | 1 |
| 1627 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18688001 | RADIOACTIVE COMPLEX OF DEGLYCOSYLATED ANTIBODY AND RADIOACTIVE PHARMACEUTICAL PRODUCT | DONOHUE, SEAN R | — | §102§103§112DP | Non-Final OA | — | Pending | Feb 29, 2024 |
| 18556577 | RADIOACTIVE ANTITUMOR AGENT | SCHLIENTZ, LEAH H | 1618 | §103 | Non-Final OA | — | Pending | Oct 20, 2023 |
| 18550479 | COMPOUND, METHOD FOR PRODUCING AND METHOD FOR STORING COMPOUND, METHOD FOR PRODUCING TARGETING AGENT, AND COMPOSITION | JARRELL, NOBLE E | 1699 | §112 | Non-Final OA | — | Pending | Sep 14, 2023 |
| 18249220 | RADIOACTIVE COMPLEXES OF ANTI-HER2 ANTIBODY, AND RADIOPHARMACEUTICAL | REYNOLDS, FRED H | 1658 | §103§112DP | Non-Final OA | 8d overdue | Pending | Apr 14, 2023 |
| 18005129 | METHOD FOR PRODUCING 225AC SOLUTION | DICKINSON, PAUL W | 1618 | §103§112 | Non-Final OA | — | Pending | Jan 11, 2023 |
| 17769657 | METHOD FOR PRODUCING RADIOACTIVE METAL-LABELED ANTIBODY | JONES, DAMERON LEVEST | 1618 | §103§112Other | Non-Final OA | — | Pending | Apr 15, 2022 |
| 17632994 | METHOD FOR PRODUCING RADIOACTIVE METAL COMPLEX | ROBINSON, MIKHAIL O'DONNEL | 1627 | §103 | Non-Final OA | — | Pending | Feb 04, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial